DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?Jason A. Roberts, Juan Carlos Montejo, Philippe G. Jorens et al.|Clinical Infectious Diseases|2014Cited by 1.1k
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Mieke Carlier, Jan J. De Waele, Sofie Carrette et al.|Critical Care|2013Cited by 212
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patientsJan J. De Waele, Jason A. Roberts, Jeffrey Lipman et al.|Intensive Care Medicine|2014Cited by 180
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohortMohd H. Abdul‐Aziz, Jason A. Roberts, Jeffrey Lipman et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 164
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients StudyMahipal Sinnollareddy, Jason A. Roberts, Jeffrey Lipman et al.|Critical Care|2015Cited by 143